Mark Sisson
speaker
665 appearances
2 recordings
2 series
first heard Sep 2025
last heard 17 Apr
Mark Sisson’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Apr 2026 with 1.
Appearances
It's a small amino acid chain.
Technically, it's less than 50 amino acids.
And so a lot of the peptides we hear about, there's so many classes today.
And I know that there's been a recent move to declassify a whole range of peptides.
from category two to category one.
I think it's interesting that we're reconsidering the safety of these peptides, but a lot of them are mimicking signaling molecules that actually occur in the human body.
And this can be useful for humans, but I think it also comes with attendant risks that we have to be careful of.
And so it's a long discussion that's very detailed, and it's case by case, and again, category by category.
I'll just talk about a couple of the
Biggest categories very quickly and then see if you want to dive in.
The biggest ones we think about today are the GLPs.
These are peptides.
So we have Ozempic, which is a GLP-1 agonist.
And then you have Moncharo or Terzepatide, which is a dual agonist between GLP and GIP.
And now a lot of people are talking about Retatrutide, which is not FDA approved.
And that's a triple agonist, GLP, GIP, and glucagon.
And so these are being used for weight loss to great effect.
And I think that what's interesting about this is that it just signals to me that we have a major obesity problem that is caused by our adulterated food supply.
And I'm a little bit taken aback that more people aren't asking that question.
So when peptides partially ameliorate a problem that didn't exist 100 years ago, which is this rampant obesity epidemic,
Showing 301–320 of 665 · page 16 of 34
← Previous
Next →